- Dr Fréderic Berget
  CEO
  frederic.berget@oncofactory.com

- Valérie Castellani-Lincontang, PhD
  Co-founder & scientific adviser
  valerie.castellani@oncofactory.com

- Céline Delloye-Bourgeois, PhD
  Co-founder & scientific adviser
  celine.delloye-bourgeois@oncofactory.com

Spin-off of the CNRS
NeuroMyoGene Institute, France

www.oncofactory.com

oncofactory



To accelerate the personalization of therapies in oncology

Our Technology

Our offers

Modeling patient tumor heteregeneity



Preclinical studies

for the industry of drug discovery

- conception of patient-derived cancer models
- validation of leads on patient tumor replicas
- identification of biomarkers predictive of drug efficacy in patients

Personalized medecine

for helping therapeutic decisions

- replicas of patient tumor for comparison of efficacy of possible treatments
- replicas of patient tumor and evaluation of proliferation and metastatic potential for clinical monitoring





oncofactory





Pediatric cancer
Neuroblastoma

Replicas created in the sites of primary tumors in patients



Monitoring of cell migration



Detection of functional markers by immunofluorescence



Profiling of genes active in the primary tumor (transcriptome analysis)

Delloye-Bourgeois et al., Cancer Cell (release in October 2017)

- Test efficacy for pediatric investigation plan
- Identification of biomarkers of patient heterogeneity

Liver Cancer

Replicas of patient tumor



Molecular characterizations



oncofactory

Prostate Cancer

Replicas of patient tumor



Detection of PSA



Test of drug efficacy

T=0h Graft
T=24h Docetaxel administration
T=48h 3D imaging tumor volume measure



Tumors derived from PC3 cells



Breast Cancer

Replicas of patient tumor

mimics of brain metastasis

Test of drug efficacy

T=0h Graft
T=24h Docetaxel administration
T=48h 3D imaging tumor volume measure

tumor replicas from a patient responsive to cisplatin



Lung Cancer

mimics of brain metastasis



Glioma

brain tumors